Wetherby Asset Management Inc Salarius Pharmaceuticals, Inc. Transaction History

Wetherby Asset Management Inc

  • $2.06 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 28, 2020
SELL
$3.02 - $5.9 $30,200 - $59,000
-10,000 Reduced 20.1%
39,746 $150,000
Q3 2019

Oct 31, 2019
BUY
$5.28 - $20.25 $262,658 - $1.01 Million
49,746 New
49,746 $271,000

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $4.11M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Wetherby Asset Management Inc Portfolio

Follow Wetherby Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email